Impact of salvage treatment phase on inotuzumab ozogamicin treatment for relapsed/refractory acute lymphoblastic leukemia: an update from the INO-VATE final study database

Affiliations

• ¹ Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
• ² Department of Medicine, Hematology and Oncology, Universitätsklinikum Münster, Münster, Germany.
• ³ Department of Hematology/Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH, USA.
• ⁴ Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
• ⁵ Department of Medicine II, University Hospital, Goethe University, Frankfurt, Germany.
• ⁶ Bristol Haematology & Oncology Centre, University Hospitals Bristol NHS Trust, Bristol, UK.
• ⁷ Section of Hematology/Oncology, Department of Medicine, University of Chicago, Chicago, IL, USA.
• ⁸ Chao Family Comprehensive Cancer Center, University of California, Irvine, Orange, CA, USA.
• ⁹ Department of Medicine, University of Washington School of Medicine, Seattle, WA, USA.
• ¹⁰ Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
• ¹¹ Global Product Development - Oncology, Pfizer Inc, Cambridge, MA, USA.
• ¹² Pfizer Pharma GmbH, Berlin, Germany.